This Article Abstract Full Text (PDF) All Versions of this Article: 109/23/2890    most recent 01.CIR.0000129310.17277.E7v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Sirol, M. Articles by Fayad, Z. A. Search for Related Content PubMed PubMed Citation Articles by Sirol, M. Articles by Fayad, Z. A. Related Collections Cardiovascular imaging agents/Techniques Pathophysiology Imaging

(Circulation. 2004;109:2890-2896.)
© 2004 American Heart Association, Inc.

Basic Science Reports

Lipid-Rich Atherosclerotic Plaques Detected by Gadofluorine-Enhanced In Vivo Magnetic Resonance Imaging

Marc Sirol, MD; Vitalii V. Itskovich, PhD; Venkatesh Mani, PhD; Juan Gilberto S. Aguinaldo, MD; John T. Fallon, MD, PhD; Bernd Misselwitz, PhD; Hanns-Joachim Weinmann, PhD; Valentin Fuster, MD, PhD; Jean-François Toussaint, MD, PhD; Zahi A. Fayad, PhD

From the Zena and Michael A. Wiener Cardiovascular Institute and Marie-Josée and Henry R. Kravis Cardiovascular Health Center (M.S., J.G.S.A., J.T.F., V.F., Z.A.F.), Imaging Science Laboratories, Department of Radiology (V.V.I., J.G.S.A., Z.A.F.), and Department of Pathology (J.T.F.), Mount Sinai School of Medicine, New York, NY; Schering AG, Berlin, Germany (B.M., H.W.); and Department of Physiology and Radioisotope, Hôpital Européen Georges Pompidou, Paris, France (J.-F.T.).

Correspondence to Zahi A. Fayad, PhD, Imaging Science Laboratories, Mount Sinai School of Medicine, Box 1030, One Gustave L. Levy Place, New York, NY 10029-6574. E-mail Zahi.Fayad{at}mssm.edu

Received December 11, 2003; revision received March 2, 2004; accepted March 4, 2004.

	Abstract

Top Abstract Introduction Methods Results Discussion Conclusion References

 
Background— MRI of specific components in atherosclerotic plaque may provide information on plaque stability and its potential to rupture. We evaluated gadofluorine in atherosclerotic rabbits using a new MR sequence that allows plaque detection within 1 hour after injection and assessed enhancement in lipid-rich and non–lipid-rich plaques.

Methods and Results— Twelve rabbits with aortic plaque and 6 controls underwent MRI before and up to 24 hours after gadofluorine injection (50 µmol/kg). Two T1-weighted, segmented gradient-echo sequences (TFL) were compared to enhance vessel wall delineation after injection: (1) an inversion-recovery prepulse (IR-TFL) or (2) a combination of inversion-recovery and diffusion-based flow suppression prepulses (IR-DIFF-TFL). With the use of IR-TFL at 1 hour after injection, the vessel wall was not delineated because of poor flow suppression; at 24 hours after injection, the enhancement was 37% (P<0.01). IR-DIFF-TFL showed significant enhancement after versus before contrast (1 hour: 164% [P<0.005]; 24 hours: 207% [P<0.001]). At 1 hour and 24 hours after injection, the contrast-to-noise ratio was higher with the use of IR-DIFF-TFL than with IR-TFL (1 hour: 13.0±7.7 versus –19.8±10.3 [P<0.001]; 24 hours: 15.2±5.9 versus 11.4±8.9, respectively [P=0.052]). There was no enhancement in the vessel wall after gadofluorine injection in the control group. A strong correlation was found (r²=0.87; P<0.001) between the lipid-rich areas in histological sections and signal intensity in corresponding MR images. This suggests a high affinity of gadofluorine for lipid-rich plaques.

Conclusions— Gadofluorine-enhanced MRI improves atherosclerotic plaque detection. The IR-DIFF-TFL method allows early detection of atherosclerotic plaque within 1 hour after gadofluorine injection.

Key Words: atherosclerosis • contrast media • magnetic resonance imaging • plaque

	Introduction

Top Abstract Introduction Methods Results Discussion Conclusion References

 
Atherosclerosis is a chronic systemic disease that affects the arterial wall of medium and large arteries. Plaques resulting from thrombotic complications of atherosclerosis may grow to obstruct the arterial lumen or to disseminate material into the bloodstream, thereby causing myocardial infarction, stroke, or peripheral vascular disease. These distinct clinical manifestations depend on the affected circulatory bed and the characteristics of individual lesions.¹ In early stages, atherosclerotic plaques may not be seen by conventional x-ray angiography or other standard imaging techniques because they develop without narrowing the arterial lumen. Despite this so-called positive arterial remodeling,² such lesions may be clinically significant even though no significant arterial lumen stenosis is detected because complications may develop suddenly.³ Our group⁴ and others⁵ have reported that noninvasive, high–spatial resolution, in vivo MRI is capable of detecting and characterizing atherosclerotic plaques. However, complete characterization and detection of high-risk plaques remain difficult.⁶ Contrast-enhanced MR has been used for plaque imaging^7–10 because it has the potential to improve the contrast-to-noise ratio (CNR) between the lumen and the vessel wall. Contrast-enhanced MR could facilitate the rapid assessment of overall atherosclerotic plaque burden, particularly in deep structures such as coronary arteries, with inherent poor signal-to-noise ratio (SNR).

Recently, gadofluorine has been shown to improve plaque detection in atherosclerotic rabbits at 48 hours after injection compared with conventional contrast-enhanced MRI.¹¹

Because gadofluorine has a higher relaxivity (R1) than Gd-DTPA, the T1 of the blood immediately after injection is very short. This leads to a high signal in the arterial lumen that obscures the vessel wall and plaque visualization, which cannot be suppressed with the use of previous MR methods (eg, single or multiple inversion-recovery [IR] preparatory pulses).

The goals of our study were to evaluate the use of gadofluorine in atherosclerotic rabbits with the use of a new MR sequence (new black-blood technique) that allows plaque detection within 1 hour after gadofluorine injection and to assess the plaque enhancement after injection (up to 24 hours) in lipid-rich (LR) and non–lipid-rich (non-LR) plaques.

	Methods

Top Abstract Introduction Methods Results Discussion Conclusion References

 
Animal Protocol
Atherosclerotic aortic lesions with fibrotic and lipidic components were induced in New Zealand White (NZW) rabbits (n=12; aged 3 months; 3.0 to 3.5 kg body wt; Covance, Princeton, NJ) by high-cholesterol diet and balloon injury, as previously described.^12,13 Rabbits were fed a high cholesterol–inducing diet (Purina Rabbit Chow, 0.1% cholesterol; Research Diets) for a minimum of 4 months. One week into the diet, aortic denudation from the renal arteries to the iliac bifurcation was performed by balloon injury (embolectomy catheter 4F) under anesthesia (ketamine 35 mg/kg IM and xylazine 7 mg/kg IM). After 6 months of atherogenic diet, the animals underwent MRI. Six age- and sex-matched NZW rabbits were used as controls; no balloon injury was performed, and no hypercholesterolemic diet was administered. The Mount Sinai Institute of Animal Care and Use Committee approved all experiments.

Contrast Agent
Gadofluorine (Schering AG) is a lipophilic, macrocyclic (1528 Da), water-soluble, gadolinium chelate complex (Gd-DO3A derivative) with a perfluorinated side chain. Gadofluorine forms 5-nm-diameter micelles or aggregates in aqueous solution.^14,15 Gadofluorine elicits an R1 relaxivity (at 37°C and 1.5 T) of 17.4 L · mmol^–1 · s^–1 in blood. The average gadofluorine plasma half-life in NZW rabbits is approximately 11 hours (B. Misselwitz, PhD, unpublished data, 2003). The majority of gadofluorine is eliminated by the hepatobiliary (66%) and renal (34%) route within 7 days.¹⁶ Because of the higher relaxivity of gadofluorine compared with conventional gadolinium chelates, we injected 50 µmol gadolinium per kilogram body weight. Gadofluorine is at a stage of research and preclinical development. No studies have been performed on humans.

Magnetic Resonance Imaging
Rabbits were sedated with ketamine/xylazine (as above) and imaged supine in a 1.5-T MRI system (Siemens). Sequential transverse images of the abdominal aorta, from the renal arteries to the iliac bifurcation, were obtained with a T1-weighted, 2D, segmented gradient-echo sequence (TFL) (1) with an IR preparatory pulse¹⁷ (IR-TFL) and (2) with a combination of IR and diffusion-based flow suppression prepulse¹⁸ (IR-DIFF-TFL). T1-weighted imaging was performed before and after administration of gadofluorine (immediately after injection [up to 1 hour] and 24 hours after injection).

The block diagram of the newly developed IR and diffusion flow–nulling preparatory pulse gradient-echo sequence (IR-DIFF-TFL) is shown in Figure 1. The nonselective (IR) adiabatic hyperbolic secant 180° radiofrequency (RF) pulse inverted magnetization of the whole volume. The diffusion module consisted of 3 rectangular RF pulses (driven equilibrium Fourier transform 90°/180°/90°), separated by diffusion gradients of variable amplitude and duration on all 3 axes (readout, phase encoding, slice).¹⁸ The pair of diffusion gradients nulls the magnetization of the flowing spins in the transverse plane. The first 90° nonselective pulse flips the magnetization into the transverse plane; the diffusion gradients, which follow, suppress the magnetization of the flowing spins. After the 180° refocusing nonselective pulse, the last 90° RF pulse restores the initial magnetization state in the nonflowing tissue spins. The IR pulse and subsequent inversion time combined with fat-saturation pulses were used to achieve different fat and muscle contrasts with respect to the vessel wall, whereas the diffusion module was used to suppress the intravascular signal independent of its T1. The diffusion module was incorporated within the inversion time period for 7 ms with a typical ratio of RF-to-gradient duration of 0.5 with first gradient moment balancing. The gradient duration-amplitude product is a measure of the diffusion module strength and hence of flow suppression.

View larger version (24K): [in this window] [in a new window]   Figure 1. Diagram of IR and diffusion-based flow suppression prepulse (IR-DIFF-TFL) sequence. The 2-dimensional IR conventional gradient-echo (GRE) sequence (IR-TFL) was modified to include diffusion module preparation for intravascular signal suppression (IR-DIFF-TFL). The fat saturation (sat.) pulse is applied during the preparation period preceding image acquisition. TR indicates repetition time; n, number of phase-encoding lines.

The IR-TFL and IR-DIFF-TFL sequence imaging parameters were as follows: repetition time/echo time=300/4 ms; excitation flip angle=20°; received bandwidth=±230 Hz per pixel; slice thickness=2.5 mm; field of view=12 cm; acquisition matrix=256x256; number of signal averages=16; and number of segments=15 (before contrast and 24 hours after injection). Immediately after injection, the number of segments was 3. A chemical fat-suppression pulse was used to null the signal from the periadventitial fat. The total acquisition time was 3 minutes before injection and for 24 hours after injection for imaging with both sequences. Acquisition time was 17 minutes (immediately after injection) with IR-DIFF-TFL. Inversion time and diffusion preparatory pulses were optimized experimentally to suppress the signal of the blood in the lumen and the signal from background tissue. A typical inversion time was 220 ms for a repetition time of 300 ms. Diffusion gradient pulse width and amplitude were 1.3 ms and 28 mT/m, respectively, with an area of 375.2 mT · s · m^–1 (b value=2035 s/m²). Optimal b value was determined experimentally. A cylindrical 17-cm-diameter RF phased-array volume coil was used.

Histopathology
Rabbits were killed after the last set of MR images (ie, 24 hours after injection) by intravenous injection of sodium pentobarbital (120 mg/kg). Aortas were excised and perfusion-fixed as previously described.^12,13 The adventitia of excised aorta was immediately marked with india ink at the posterior face of the artery to facilitate matching of the histological slides and MR images. Serial sections of the aorta were cut at 3-mm intervals. Coregistration was performed carefully by utilizing the position of the renal arteries and iliac bifurcation.^12,13,19 The selected aortic specimens were embedded in paraffin, and 5-µm-thick sections were cut and stained with hematoxylin-eosin (H&E) or with Masson’s trichrome elastin. An independent experienced pathologist blinded to the MR findings performed the histological analyses following the classification from the Committee on Vascular Lesions of the Council of Atherosclerosis, American Heart Association.³ All tissue components (loose fibrous, media, dense fibrous, fibrocellular [cap], lipid/necrotic [core]) present in histopathological specimens were identified.^20,21 Tissue component areas were traced manually. Two different areas were distinguished for further analysis: LR and non-LR areas. LR area was defined as the paler pink plaque areas in each quadrant of aortic sections (H&E).

Image and Data Analysis
Images were analyzed with ImagePro Plus (Media Cybernetics). For each time point, a total of 3 slices at different locations were analyzed along the abdominal aorta. Wall and lumen signal intensities (SI) were determined with standard region-of-interest (ROI) measurements on the corresponding MR images (n=108). An ROI containing no motion artifacts was placed outside of the animal to measure the SD of the noise signal. Both enhancement ratio (ER) of the SI (ER=SI_wall-post/SI_wall-pre) and normalized CNR (CNR=SI_wall–SI_lumen/SD_noise) were calculated, where SI_wall-post is signal intensity of the arterial wall after contrast injection and SI_wall-pre is signal intensity of the arterial wall before contrast injection. An experienced observer drew all ROI. Both ER and CNR were calculated at 3 different time points: before gadofluorine injection, 1 hour after injection, and 24 hours after injection. Serial comparisons among the 3 sets of MR images from the same animal at the same aortic site were performed. The standardized protocol ensured identical slice position for the precontrast and all postcontrast images. The MR images were also matched with corresponding histopathological sections of the aortic specimens, as previously described.^12,13 At 24 hours after injection, MR images and the matched histopathological sections were divided into 4 quadrants. SI and CNR were calculated for each quadrant of MR images and were thereafter classified as LR or non-LR on the basis of histological sections, as explained earlier. The MR-derived SI and CNR were correlated with the lipid content for each image quadrant. Only the corresponding area on MR image was taken when compared with CNR.

Statistical Analysis
One-way ANOVA was used to compare derived parameters from IR-TFL and IR-DIFF-TFL images at the same sites in the abdominal aorta for the 3 time points (before injection, 1 hour after injection, 24 hours after injection) with a Tukey test for post hoc comparisons. All probabilities are 2-sided and expressed as mean±SD. Probability values <0.05 were considered statistically significant.

	Results

Top Abstract Introduction Methods Results Discussion Conclusion References

 
All the MR images (n=108) were interpretable. MRI before gadofluorine, with the use of the conventional method (IR-TFL) and newly developed sequence (IR-DIFF-TFL), showed no enhancement in the abdominal aorta in either atherosclerotic (n=12) or control (n=6) rabbits. CNR in the atherosclerotic group was 8.1±5.1 (conventional) and 6.1±4.7 (new sequence) (P=NS) and was 8.4±7.0 and 6.7±5.5, respectively, in the control group (P=NS).

In the atherosclerotic group (n=12), vessel lumen appeared bright with the conventional method and black with the new sequence immediately after gadofluorine injection (Figure 2). The intravascular blood signal was suppressed with the new sequence immediately after contrast injection compared with the conventional method, as indicated by CNR: 13.0±7.7 versus –19.8±10.3, respectively (P<0.001). The negative CNR value with the conventional method was due to the high aortic intraluminal SI compared with SI from the adjacent aortic wall. In this group, the enhancement of the aortic wall with the new sequence was 164% at 1 hour after injection compared with precontrast imaging (P<0.005). ER was higher at 1 hour with the new sequence compared with the conventional method (2.64 versus 0.47, respectively; P<0.001). At 24 hours after injection, with the new sequence, the enhancement was 207% compared with before contrast (P<0.001). ER was 3.07 with the new sequence and 1.37 with the conventional method (P=0.052). There was a trend toward higher enhancement of the aortic wall with the new sequence versus the conventional method. The CNR values were 15.2±5.9 (new sequence) and 11.4±8.9 (conventional method). No enhancement was present in the aortic wall in the control group (n=6) at 1 hour or 24 hours after injection.

View larger version (119K): [in this window] [in a new window]   Figure 2. Transverse T1-weighted MR images of atherosclerotic rabbit abdominal aorta at 3 different time points: precontrast imaging (left), 1 hour after gadofluorine injection (middle), and 24 hours after gadofluorine injection (right). A, Conventional IR-TFL sequence; B, newly developed IR-DIFF-TFL sequence. At 1 hour after injection, aortic luminal blood signal (*) is suppressed with the use of IR-DIFF-TFL (B) compared with IR-TFL (A). Signal intensity (ie, plaque enhancement) is higher 1 hour after injection with IR-DIFF-TFL compared with IR-TFL (P<0.001).

In the atherosclerotic group, at 24 hours after injection, pronounced enhancement occurred along the abdominal aorta, but regions with different enhancement intensity were easily discerned. Figure 3 shows the heterogeneous enhancement of the plaque along the aorta. These plaques exhibited various histological features such as LR areas, collagen content, and fibrous cap thickness. At 24 hours after injection, each plaque was analyzed in different quadrants on histopathology sections and on MR images (Figure 4 and Figure 5 ). Although the pattern of enhancement was circular in all transverse MR images analyzed (n=108), measurement of SI and CNR was higher in the LR quadrants compared with non-LR quadrants, as shown by histopathology (P<0.05, P<0.001, respectively) (Figure 6). A strong correlation (r²=0.87; P<0.001) was found between CNR at 24 hours after injection and LR areas, suggesting a high affinity of gadofluorine for lipid components.

View larger version (109K): [in this window] [in a new window]   Figure 3. In vivo MR images (sagittal [A] and transverse [B]) and corresponding histopathological sections of atherosclerotic rabbit abdominal aorta. A, Heterogeneous plaque enhancement along the aortic length with the use of IR-DIFF-TFL sequence 24 hours after gadofluorine injection. Three different slice locations (1, 2, 3) were chosen for transverse MR images (B) and histopathological analysis (C). B, Differences in signal intensity depending on the slice locations (1, 2, 3). Corresponding histopathological sections, stained with H&E, exhibit various features, with plaque composition details shown in D. Magnified areas are indicated by squares in C. At level 1, enhancement is heterogeneous (11 to 2 o’clock) because of accumulation of lipids within the fibrous area. At level 2, large lipid core (4 to 7 o’clock) corresponds to highest enhancement within the plaque. Plaque at level 3 is mainly composed of lipids (10 to 5 o’clock) with perfect matching of the highest plaque enhancement. Ad indicates adventitia; F, loose fibrous; FC, fibrous cap; L, lumen; LC, lipid core; and M, macrophages.

View larger version (79K): [in this window] [in a new window]   Figure 4. In vivo T1-weighted MR transverse image of atherosclerotic rabbit abdominal aorta 24 hours after gadofluorine injection with the use of IR-DIFF-TFL (A). Magnified panel (B) shows plaque enhancement after injection. Corresponding histopathological section is shown in D. The combined Masson’s trichrome elastin staining allows characterization of different plaque components (magnification x4). MR images and histopathological sections were divided into 4 quadrants for further analysis (C). The appearance of MR image correlates closely with the matched histopathological section shown in D. Ad indicates adventitia; FC, fibrous cap; L, lumen; and LC, lipid core.

View larger version (28K): [in this window] [in a new window]   Figure 5. Diagram depicts CNR (A) and ER (B) for atherosclerotic (AT) rabbit group and control group at different time points, comparing values between conventional method (IR-TFL) and new sequence (IR-DIFF-TFL). Note that CNR for the control group was similar for before and after gadofluorine imaging. **P<0.001; *P<0.005; difference did not reach statistical significance.

View larger version (13K): [in this window] [in a new window]   Figure 6. Relationship between non-LR and LR areas within atherosclerotic plaque as shown by histopathology. Shown are SI (A) and CNR (B) measured on MR images 24 hours after gadofluorine injection with the use of IR-DIFF-TFL. *P<0.01; **P<0.001.

	Discussion

Top Abstract Introduction Methods Results Discussion Conclusion References

 
Contrast Agent for Plaque Characterization
Gadofluorine is a macrocyclic gadolinium-based contrast agent with high relaxivity, long plasma half-life, water solubility, and lipophilicity compared with Gd-DTPA.^14,15 In Watanabe heritable hyperlipidemic rabbits, with the use of a T1-weighted sequence (conventional IR-TFL) at 48 hours after contrast injection, gadofluorine enhanced atherosclerotic plaque and improved plaque detection compared with non–contrast-enhanced MRI.¹¹ Few studies have been performed with this new class of contrast agent.^14–16,22 The exact mechanism of gadofluorine uptake and accumulation into the atherosclerotic plaque is still unknown. It might leak out of the lumen into plaques because of enhanced endothelial permeability in atherosclerotic plaques.^11,23 It can also penetrate plaque through the adventitia as a result of increased vasa vasorum feeding the plaque neovasculature.²⁴ Future studies are under way to determine the uptake and specific accumulation.

Conventional contrast-enhanced MR in which gadolinium chelates are used alters the MR proton relaxation of the imaged tissue. These contrast agents do not penetrate phospholipid cellular membranes because of their highly hydrophilic properties.²⁵ These agents are confined to the extracellular space after intravenous administration, do not bind to plasma proteins, and are eliminated without being metabolized by the kidneys.^26,27 In atherosclerotic rabbits, after Gd-DTPA had cleared from the blood, no aortic wall segment enhancement could be detected.¹¹ Gadofluorine forms aggregates or micelles in aqueous solution, and, because of its lipophilic properties, the compound has the ability to penetrate and accumulate within the plaque after intravenous injection.¹¹ In our experience, gadofluorine lasts within the plaque no more than 72 hours after injection, but future studies are needed.

We demonstrate in this study that due to the high T1 relaxivity (R1) of gadofluorine compared with gadolinium chelate contrast agents, the use of conventional T1-weighted imaging (ie, IR-TFL) is not adequate for wall enhancement detection immediately after injection. Atherosclerotic plaque detection was possible with the use of a combination of IR-DIFF-TFL and gadofluorine as early as 1 hour after injection because of the intravascular signal suppression from the diffusion preparation. We also demonstrate that 24 hours after injection, enhancement of plaques was heterogeneous. Although this study was not designed to assess plaque characterization, we found a strong correlation between LR areas in histological sections and the high CNR in matched MR images, suggesting a high affinity of gadofluorine for LR plaques. Furthermore, plaques with low lipid content, such as fibrocellular plaques, had a weaker enhancement compared with the LR areas. Fibrocellular plaques are usually considered less vulnerable plaques than plaques with a LR core and/or with a thin fibrous cap.²⁸ This affinity to the LR areas may facilitate imaging and characterization of atherosclerotic plaques. More work must be done to confirm these findings, especially to better define the relation between gadofluorine, lipids, and other plaque components.

MR Technique
The use of diffusion gradients has been considered an efficient way of suppressing flowing spins. Flow suppression depends on vessel size²⁹ and is more efficient in large arteries (eg, aorta), where the flow is laminar.^18,30 The IR pulse was used to suppress the signal from the perivascular tissues (fat and muscle), and the diffusion module was used for suppression of the blood signal by a mechanism independent of longitudinal relaxation. This was needed because of the relatively long gadofluorine plasma half-life, high relaxivity, and short T1 in the lumen during the 24 hours after injection. Fat suppression was used to null signal from periadventitial fat, which can obscure the vessel wall because of chemical shift.⁴ In contrast to periadventitial fat, the relatively immobile lipid protons in plaque have been shown to contribute only 10% of the signal,³¹ and thus fat suppression has a negligible effect on the plaque itself.³² The present study demonstrates that the newly developed T1-weighted IR-DIFF-TFL sequence provides effective and improved atherosclerotic plaque detection after gadofluorine in vivo imaging. As shown here, the use of new high-relaxivity contrast agents will most likely necessitate the utilization of novel MRI methods to take advantage of the contrast agent properties.

The use of gadofluorine-enhanced imaging, as shown in our study, can be combined with high-resolution, black- and bright-blood, stationary and dynamic, multicontrast-weighted (eg, T1-weighted, T2-weighted, proton density–weighted, before and after gadofluorine) imaging for improved plaque boundary³³ and component assessments^5,9,34 and should be a subject of future studies.

	Conclusion

Top Abstract Introduction Methods Results Discussion Conclusion References

 
Contrast-enhanced MR with the gadofluorine contrast agent facilitates and improves plaque detection in NZW atherosclerotic rabbits compared with conventional contrast-enhanced and non–contrast-enhanced MRI. We developed a new T1-weighted sequence (IR-DIFF-TFL) that allows in vivo detection of atherosclerotic plaque within the first hour after injection of gadofluorine because of its capability of suppressing the intravascular blood signal in a 1.5-T MR clinical system. The strong correlation between LR areas, as shown by histopathology and CNR in matched MR images, suggests a high affinity of gadofluorine for plaque LR regions. Gadofluorine-enhanced MRI may be helpful in detection of atherosclerotic plaque burden and components and assessment of the efficacy of antiatherogenic therapies.

	Acknowledgments

 
This work was supported in part by the Fédération Française de Cardiologie, Paris, France (Dr Sirol), NIH/NHLBI R01HL071021, Schering AG (Berlin, Germany), and the Mount Sinai Consortium for Cardiovascular Imaging Technology (Dr Fayad).

	References

Top Abstract Introduction Methods Results Discussion Conclusion References

 
1. Fuster V, Fayad ZA, Badimon JJ. Acute coronary syndromes: biology. Lancet. 1999; 353 (suppl 2): SII5–SII9.[Medline] [Order article via Infotrieve]

2. Glagov S, Weisenberg E, Zarins CK, et al. Compensatory enlargement of human atherosclerotic coronary arteries. N Engl J Med. 1987; 316: 1371–1375.[Abstract]

3. Stary HC, Chandler AB, Dinsmore RE, et al. A definition of advanced types of atherosclerotic lesions and a histological classification of atherosclerosis: a report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. Circulation. 1995; 92: 1355–1374.[Abstract/Free Full Text]

4. Fayad ZA, Fuster V, Fallon JT, et al. Noninvasive in vivo human coronary artery lumen and wall imaging using black-blood magnetic resonance imaging. Circulation. 2000; 102: 506–510.[Abstract/Free Full Text]

5. Yuan C, Mitsumori LM, Beach KW, et al. Carotid atherosclerotic plaque: noninvasive MR characterization and identification of vulnerable lesions. Radiology. 2001; 221: 285–299.[Abstract/Free Full Text]

6. Cai JM, Hatsukami TS, Ferguson MS, et al. Classification of human carotid atherosclerotic lesions with in vivo multicontrast magnetic resonance imaging. Circulation. 2002; 106: 1368–1373.[Abstract/Free Full Text]

7. Yuan C, Kerwin WS, Ferguson MS, et al. Contrast-enhanced high resolution MRI for atherosclerotic carotid artery tissue characterization. J Magn Reson Imaging. 2002; 15: 62–67.[CrossRef][Medline] [Order article via Infotrieve]

8. Wasserman BA, Smith WI, Trout HH III, et al. Carotid artery atherosclerosis: in vivo morphologic characterization with gadolinium-enhanced double-oblique MR imaging initial results. Radiology. 2002; 223: 566–573.[Abstract/Free Full Text]

9. Kerwin W, Hooker A, Spilker M, et al. Quantitative magnetic resonance imaging analysis of neovasculature volume in carotid atherosclerotic plaque. Circulation. 2003; 107: 851–856.[Abstract/Free Full Text]

10. Kooi ME, Cappendijk VC, Cleutjens KB, et al. Accumulation of ultrasmall superparamagnetic particles of iron oxide in human atherosclerotic plaques can be detected by in vivo magnetic resonance imaging. Circulation. 2003; 107: 2453–2458.[Abstract/Free Full Text]

11. Barkhausen J, Ebert W, Heyer C, et al. Detection of atherosclerotic plaque with gadofluorine-enhanced magnetic resonance imaging. Circulation. 2003; 108: 605–609.[Abstract/Free Full Text]

12. Helft G, Worthley SG, Fuster V, et al. Atherosclerotic aortic component quantification by noninvasive magnetic resonance: an in vivo study in rabbits. J Am Coll Cardiol. 2001; 37: 1149–1154.[Abstract/Free Full Text]

13. Worthley SG, Helft G, Fuster V, et al. Serial In vivo MRI documents arterial remodeling in experimental atherosclerosis. Circulation. 2000; 101: 586–589.[Abstract/Free Full Text]

14. Misselwitz B, Platzek J, Raduchel B, et al. Gadofluorine 8: initial experience with a new contrast medium for interstitial MR lymphography. Magma. 1999; 8: 190–195.[CrossRef][Medline] [Order article via Infotrieve]

15. Staatz G, Nolte-Ernsting CCA, Adam GB, et al. Interstitial T1-weighted MR lymphography: lipophilic perfluorinated gadolinium chelates in pigs. Radiology. 2001; 220: 129–134.[Abstract/Free Full Text]

16. Misselwitz B, Platzek J, Weinmann HJ. Early intravenous MR lymphography with gadofluorine M in rabbits. Radiology. In press.

17. Edelman R, Wallner B, Singer A, et al. Segmented turboFLASH: method for breath-hold MR imaging of the liver with flexible contrast. Radiology. 1990; 177: 515–521.[Abstract/Free Full Text]

18. Pell GS, Lewis DP, Branch CA. Pulsed arterial spin labeling using turboFLASH with suppression of intravascular signal. Magn Reson Med. 2003; 49: 341–350.[CrossRef][Medline] [Order article via Infotrieve]

19. Fayad ZA, Fallon JT, Shinnar M, et al. Noninvasive in vivo high-resolution magnetic resonance imaging of atherosclerotic lesions in genetically engineered mice. Circulation. 1998; 98: 1541–1547.[Abstract/Free Full Text]

20. Garvey W. Modified elastic tissue–Masson trichrome stain. Stain Technol. 1984; 59: 213–216.[Medline] [Order article via Infotrieve]

21. Mitchinson MJ. Insoluble lipids in human atherosclerotic plaques. Atherosclerosis. 1982; 45: 11–15.[CrossRef][Medline] [Order article via Infotrieve]

22. Shimada M, Yoshikawa K, Suganuma T, et al. Interstitial magnetic resonance lymphography: comparative animal study of gadofluorine 8 and gadolinium diethylenetriamine-pentaacetic acid. J Comput Assist Tomogr. 2003; 27: 641–646.[CrossRef][Medline] [Order article via Infotrieve]

23. Colangelo S, Langille BL, Steiner G, et al. Alterations in endothelial F-actin microfilaments in rabbit aorta in hypercholesterolemia. Arterioscler Thromb Vasc Biol. 1998; 18: 52–56.[Abstract/Free Full Text]

24. Purushothaman K-R, Fuster V, O’Connor WN, et al. Neovascularization is the most powerful independent predictor for progression to disruption in high-risk atherosclerotic plaques. J Am Coll Cardiol. 2003; 41 (suppl 2): 352–353.

25. Merbach AA, Toth E. The Chemistry of Contrast Agents in Medical Magnetic Resonance Imaging. Chichester, UK: John Wiley & Sons; 2001.

26. Weinmann HJ, Laniado M, Mutzel W. Pharmacokinetics of GdDTPA/dimeglumine after intravenous injection into healthy volunteers. Physiol Chem Phys Med NMR. 1984; 16: 167–172.[Medline] [Order article via Infotrieve]

27. Niendorf HP, Alhassan A, Balzer T, et al. Safety and Risk of Gadolinium-DTPA: Extended Clinical Experience After More Than 20 Million Applications. 3rd rev ed. Berlin, Germany: Blackwell Wissenschafts-Verlag GmbH; 1996.

28. Maseri A, Fuster V. Is there a vulnerable plaque? Circulation. 2003; 107: 2068–2071.[Free Full Text]

29. Henkelman RM, Neil JJ, Xiang QS. A quantitative interpretation of IVIM measurements of vascular perfusion in the rat brain. Magn Reson Med. 1994; 32: 464–469.[Medline] [Order article via Infotrieve]

30. Jara H, Yu BC, Caruthers SD, et al. Voxel sensitivity function description of flow-induced signal loss in MR imaging: implications for black-blood MR angiography with turbo spin-echo sequences. Magn Reson Med. 1999; 41: 575–590.[CrossRef][Medline] [Order article via Infotrieve]

31. Toussaint JF, Southern JF, Fuster V, et al. T2-weighted contrast for NMR characterization of human atherosclerosis. Arterioscler Thromb Vasc Biol. 1995; 15: 1533–1542.[Medline] [Order article via Infotrieve]

32. Toussaint JF, LaMuraglia GM, Southern JF, et al. Magnetic resonance images lipid, fibrous, calcified, hemorrhagic, and thrombotic components of human atherosclerosis in vivo. Circulation. 1996; 94: 932–938.[Abstract/Free Full Text]

33. Zhang S, Cai J, Luo Y, et al. Measurement of carotid wall volume and maximum area with contrast-enhanced 3D MR imaging: initial observations. Radiology. 2003; 228: 200–205.[Abstract/Free Full Text]

34. Fayad ZA, Fuster V, Nikolaou K, et al. Computed tomography and magnetic resonance imaging for noninvasive coronary angiography and plaque imaging: current and potential future concepts. Circulation. 2002; 106: 2026–2034.[Free Full Text]

This article has been cited by other articles:

				J. A. Ronald, Y. Chen, A. J.-L. Belisle, A. M. Hamilton, K. A. Rogers, R. A. Hegele, B. Misselwitz, and B. K. Rutt Comparison of Gadofluorine-M and Gd-DTPA for Noninvasive Staging of Atherosclerotic Plaque Stability Using MRI Circ Cardiovasc Imaging, May 1, 2009; 2(3): 226 - 234. [Abstract] [Full Text] [PDF]

				I. Koktzoglou, A. Kirpalani, T. J. Carroll, D. Li, and J. C. Carr Dark-Blood MRI of the Thoracic Aorta with 3D Diffusion-Prepared Steady-State Free Precession: Initial Clinical Evaluation Am. J. Roentgenol., October 1, 2007; 189(4): 966 - 972. [Abstract] [Full Text] [PDF]

				D. E. Sosnovik, M. Nahrendorf, and R. Weissleder Molecular Magnetic Resonance Imaging in Cardiovascular Medicine Circulation, April 17, 2007; 115(15): 2076 - 2086. [Full Text] [PDF]

				D. Maintz, M. Ozgun, A. Hoffmeier, R. Fischbach, W. Y. Kim, M. Stuber, W. J. Manning, W. Heindel, and R. M. Botnar Selective coronary artery plaque visualization and differentiation by contrast-enhanced inversion prepared MRI Eur. Heart J., July 2, 2006; 27(14): 1732 - 1736. [Abstract] [Full Text] [PDF]

				R. L. Wilensky, H. K. Song, and V. A. Ferrari Role of magnetic resonance and intravascular magnetic resonance in the detection of vulnerable plaques. J. Am. Coll. Cardiol., April 18, 2006; 47(8 Suppl): C48 - C56. [Abstract] [Full Text] [PDF]

				S. A. Wickline, A. M. Neubauer, P. Winter, S. Caruthers, and G. Lanza Applications of Nanotechnology to Atherosclerosis, Thrombosis, and Vascular Biology Arterioscler. Thromb. Vasc. Biol., March 1, 2006; 26(3): 435 - 441. [Abstract] [Full Text] [PDF]

				F. L. Ruberg, J. Viereck, A. Phinikaridou, Y. Qiao, J. Loscalzo, and J. A. Hamilton Identification of cholesteryl esters in human carotid atherosclerosis by ex vivo image-guided proton MRS J. Lipid Res., February 1, 2006; 47(2): 310 - 317. [Abstract] [Full Text] [PDF]

				F. Hyafil, J.-P. Laissy, M. Mazighi, D. Tchetche, L. Louedec, H. Adle-Biassette, S. Chillon, D. Henin, M.-P. Jacob, D. Letourneur, et al. Ferumoxtran-10-Enhanced MRI of the Hypercholesterolemic Rabbit Aorta: Relationship Between Signal Loss and Macrophage Infiltration Arterioscler. Thromb. Vasc. Biol., January 1, 2006; 26(1): 176 - 181. [Abstract] [Full Text] [PDF]

				V. Fuster, Z. A. Fayad, P. R. Moreno, M. Poon, R. Corti, and J. J. Badimon Atherothrombosis and High-Risk Plaque: Part II: Approaches by Noninvasive Computed Tomographic/Magnetic Resonance Imaging J. Am. Coll. Cardiol., October 4, 2005; 46(7): 1209 - 1218. [Abstract] [Full Text] [PDF]

				M. Sirol, V. Fuster, J. J. Badimon, J. T. Fallon, J.-F. Toussaint, and Z. A. Fayad Chronic Thrombus Detection With In Vivo Magnetic Resonance Imaging and a Fibrin-Targeted Contrast Agent Circulation, September 13, 2005; 112(11): 1594 - 1600. [Abstract] [Full Text] [PDF]

				V. Fuster and R. J. Kim Frontiers in Cardiovascular Magnetic Resonance Circulation, July 5, 2005; 112(1): 135 - 144. [Full Text] [PDF]

This Article Abstract Full Text (PDF) All Versions of this Article: 109/23/2890    most recent 01.CIR.0000129310.17277.E7v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Sirol, M. Articles by Fayad, Z. A. Search for Related Content PubMed PubMed Citation Articles by Sirol, M. Articles by Fayad, Z. A. Related Collections Cardiovascular imaging agents/Techniques Pathophysiology Imaging